Program Description
Acute lymphoblastic leukemia (ALL) is a hematologic malignancy that involves proliferation of immature lymphoid cells in the bone marrow, peripheral blood, and other organs. Current treatment regimens for ALL consist of multiple chemotherapy agents delivered throughout several distinct phases of therapy. The addition of asparaginase to these regimens has led to improvements in remission rates and increased survival for patients with ALL. As part of the multidisciplinary care team, oncology pharmacists contribute to improved patient outcomes and help ensure the safe and effective use of systemic therapies. Through this activity, pharmacists will be equipped with the knowledge necessary to effectively monitor patients with ALL for asparaginase-associated toxicities as well as ensure proper management of hypersensitivity reactions and other adverse effects.
Target audience: Oncology Pharmacists
Type of activity: Application
Release date: November 21, 2023
Expiration date: January 21, 2024
Time to complete activity: 1.0 hour
Learner level: Foundational; Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explore asparaginase-containing regimens for adults/young adults with acute lymphoblastic leukemia (ALL) considering guideline recommendations and recent clinical evidence
- Identify appropriate strategies to minimize hypersensitivity reactions of asparaginase therapy in adult/young adult patients with ALL, in accordance with guideline-recommended protocols
- Classify the pharmacist’s role in preventing, monitoring, and managing asparaginase-related adverse effects in adult/young adult patients with ALL
